Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;11:615986. doi: 10.3389/fonc.2021.615986

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Zhu, Xu, Li, Guan, Li and Sun

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

MRI images in a 18-year-old male patient with DF of left calf muscle with imatinib treatment (arrows). Pre-therapy (A, F) diameter, 21.0 mm; On T2WI, V_T = 5,477 mm³, V_HI = 418 mm³, HI = 7.5% (grade = 0); On T1 CE, V_T = 5,238 mm³, V_HI = 5,238 mm³, HI = 100% (grade = 3). Segmentation of V_T (B, G, red zonex) and segmentation of V_HI (C, H, green zone). First follow-up at 3 months since treatment with imatinib (D, I) diameter, 25.0 mm indicates a 19.0% increase in tumor size. The tumor response assessment is SD, according to RECIST1.1. Second follow-up at 5 months since treatment with imatinib (E, J) diameter, 36.0 mm indicates a 71.4% increase in tumor size. The tumor response assessment is PD, according to RECIST1.1.